Publikationen in Zusammenarbeit mit Forschern von Hospital General Universitario Gregorio Marañón (62)

2025

  1. Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries

    Arthritis Research and Therapy, Vol. 27, Núm. 1

  2. Different giant cell arteritis phenotypes may present distinct types of ischaemic complications

    Clinical and Experimental Rheumatology, Vol. 43, Núm. 4, pp. 668-673

  3. Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    Health Policy, Vol. 156

  4. Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis

    Joint Bone Spine, Vol. 92, Núm. 3

  5. Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registry

    Arthritis Research and Therapy, Vol. 27, Núm. 1

  6. Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation study

    BMC Rheumatology, Vol. 9, Núm. 1

  7. One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry

    Reumatologia Clinica, Vol. 21, Núm. 5

  8. Predictors of Secukinumab Treatment Response and Continuation in Axial Spondyloarthritis: Results From the EuroSpA Research Collaboration Network

    Journal of Rheumatology, Vol. 52, Núm. 6, pp. 572-582

  9. Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors

    Rheumatology, Vol. 64, Núm. 4, pp. 1853-1863

  10. Use of Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis in Spain and Barriers to Implementation: A Delphi Study

    Advances in Therapy, Vol. 42, Núm. 10, pp. 4904-4915

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

  2. Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

    Arthritis Care and Research, Vol. 76, Núm. 11, pp. 1558-1565

  3. Correction to: Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care (BMC Rheumatology, (2024), 8, 1, (31), 10.1186/s41927-024-00401-x)

    BMC Rheumatology

  4. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

    RMD Open, Vol. 10, Núm. 3

  5. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  6. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

  7. Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry

    The Journal of rheumatology, Vol. 51, Núm. 9, pp. 877-883

  8. Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care

    BMC Rheumatology, Vol. 8, Núm. 1

  9. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 65

  10. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2